We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Clinical Data on New Assay Panel Demonstrates Accurate Assessment of Pancreatic Cancer Risk

By LabMedica International staff writers
Posted on 31 Jul 2025

Pancreatic cancer is the third-deadliest cancer in the US. More...

Early detection is key to improving the survival rate. One window to early diagnosis is pancreatic cystic lesions (PCL), a known precursor lesion for pancreatic cancer. Patients diagnosed with pancreatic cysts are at higher risk of pancreatic cancer, but many of these cystic lesions are benign, so risk stratification tools are critical. Now, new clinical validation data presented at ADLM 2025 highlights recent findings related to the stratification of PCLs, a complex and increasingly common clinical challenge.

The work builds on PanCystPro, a CLIA-cleared assay from Amplified Sciences (West Lafayette, IN, USA), which is designed to assist clinicians in the risk stratification of patients diagnosed with PCL by distinguishing between mucinous and non-mucinous cysts using comparatively less fluid. The PanCystPro test uses a proprietary platform that enables ultrasensitive detection of multiple biomarkers in small volumes of pancreatic cyst fluid. This multianalyte assay utilizes a robust algorithm and features a novel protease activity assay, enabling better biological insight to inform risk stratification of PCL. This multianalyte assay utilizes a robust algorithm and features a novel protease activity assay, enabling better biological insight to inform risk stratification of PCL.

This highly accurate test allows clinicians to define low-risk and/or benign pancreatic cysts, ruling out potential for malignancy, thus resulting in significant cost savings and patient peace of mind. In testing among several clinical cohorts, the assay provides the advantages of increased accuracy, high negative predictive value, a robust panel of biomarkers including the measurement of important protease activity, and a significantly reduced volume of pancreatic cyst fluid required. This test will address the need of gastroenterologists, pancreatic biliary surgeons, and other clinicians for better diagnostic tests to manage patients diagnosed with pancreatic cysts. At ADLM 2025, Mini Thomas, PhD, Principal Scientist, is highlighting recent findings related to the stratification of PCLs.

“The data show high accuracy and predictive value in grading dysplasia in pancreatic cystic lesions—a key risk factor for pancreatic cancer. These results highlight the potential of our diagnostic platform BioMatra and support the assay panel’s ability to reliably classify dysplasia in high-risk lesions, such as Intraductal Papillary Mucinous Neoplasms (IPMNs),” said Diana Caldwell, CEO of Amplified Sciences. “With minimal sample volume requirements, this approach will support earlier risk stratification, an important step given that nearly 80% of pancreatic cancer cases are diagnosed at a late stage.”

Related Links:
Amplified Sciences


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Hematology Analyzer
Medonic M32B
New
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Early and effective screening for gestational diabetes mellitus is becoming increasingly important (Photo courtesy of Shutterstock)

First-Trimester Blood Test Accurately Predicts Gestational Diabetes

Gestational diabetes mellitus (GDM) affects many pregnancies and is typically detected midway through pregnancy, often too late to prevent complications. Women diagnosed late face increased risks such... Read more

Hematology

view channel
Image: Platelets sequester cfDNA during circulation (Murphy L. et al., Science, 2025; DOI: 10.1126/science.adp3971)

Platelets Could Improve Early and Minimally Invasive Detection of Cancer

Platelets are widely recognized for their role in blood clotting and scab formation, but they also play a crucial role in immune defense by detecting pathogens and recruiting immune cells.... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.